Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31199058 | 0.82 | MAPT (0.44) | MAPTTGFBR1IRAK4 | |
| SCHEMBL24095465 | 0.82 | MAPT (0.44) | MAPTTGFBR1IRAK4NPC1RAB9A | |
| SCHEMBL2009561 | 0.82 | TGFBR1 (0.51) | MAPTTGFBR1HTR3EHTR3BHTR3A | |
| SCHEMBL25336337 | 0.81 | KDM4E (0.52) | MAPTTGFBR1RECQLIRAK4KDM4E | |
| SCHEMBL25333352 | 0.79 | RAB9A (0.43) | IRAK4KDM4ENPC1RAB9A | |
| SCHEMBL6340017 | 0.79 | CYP1A2 (0.56) | MAPTTGFBR1HTR3EHTR3BHTR3A | |
| SCHEMBL31199123 | 0.77 | MEN1 (0.50) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL731856 | 0.77 | MEN1 (0.50) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL20028701 | 0.77 | KDM4E (0.48) | MAPTTGFBR1RECQLIRAK4KDM4E | |
| SCHEMBL29014091 | 0.77 | IRAK4 (0.40) | MAPTRECQLIRAK4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3922631-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-BETA R1 KINASE INHIBITOR | Jiangsu AoSaiKang Pharmaceutical Co., Ltd. (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-9938289-B2 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9260450-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2527345-B1 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS INC (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9090625-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | Medicis Phamaceutical Corporation (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2074128-B1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | MEDICIS PHARMACEUTICAL CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8455512-B2 | Therapeutic pyrazolyl thienopyridines | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| US-7964612-B2 | Therapeutic pyrazolyl thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | MAPT 3677/4885TGFBR1 1/4885HTR3E 2736/4885 |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | MAPT 3677/4885TGFBR1 1/4885HTR3E 2736/4885 |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | TGFBR1, SMAD3, TGFBR2 | MAPT 3677/4885TGFBR1 1/4885HTR3E 2736/4885 |
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | TGFBR1, TGFBR2, TGFB1 | MAPT 2338/4885TGFBR1 1/4885HTR3E 2643/4885 |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | MAPT 3677/4885TGFBR1 1/4885HTR3E 2736/4885 |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | ACVR1, TGFBR1, ACVRL1 | MAPT 4596/4885TGFBR1 2/4885HTR3E 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.